XML 23 R7.htm IDEA: XBRL DOCUMENT v3.5.0.1
Statements of Cash Flows - USD ($)
 9 Months Ended 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Jun. 30, 2015
Jun. 30, 2014
Cash flows from operating activities        
Net loss $ (12,882,626) $ (5,567,960) $ (7,723,404) $ (5,578,690)
Stock-based compensation expense 547,109 749,810 1,017,938 499,690
Depreciation, amortization and accretion 433,471 73,746 118,202 97,476
Amortization of debt issuance costs 178,338 0    
Amortization of beneficial conversion feature 3,942,613 0    
Derivative expense 50,054 0    
Amortization of prepaid research and development - related party 91,487 91,488 121,984 35,579
Deferred taxes 0 (23,910) (23,910) (813,697)
Adjustments to reconcile net loss to net cash used in operating activities:        
Decrease (increase) in accounts receivable 72,784 (1,036) (157,058) 0
(Increase) in inventory (581,910) (11,233) (39,442) 0
(Increase) decrease in prepaid expenses, other (572,238) 496,322 150,434 (497,322)
Increase in prepaid research and development - related party 0 (150,000) (150,000) (465,000)
(Decrease) in accounts payable and accrued liabilities (18,319) (103,158)    
Increase in accounts payable     547,314 421,870
(Decrease) in related party payable 0 (392,509)    
Increase in accrued compensation 591,451 98,949 196,503 0
(Decrease) increase in interest payable to Ampio     (46,002) 46,002
Increase (decrease) in interest payable 208,941 (42,673) (561,059) 561,059
Increase in deferred rent 10,560 0    
(Decrease) increase in deferred revenue (64,286) (64,286) (85,714) 191,071
Net cash used in operating activities (7,992,571) (4,846,450) (6,634,214) (5,501,962)
Cash flows used in investing activities        
Deposits 1,998 (1,998) (4,886) 0
Purchases of fixed assets (203,577) 0 0 (9,298)
Purchase of Primsol business (540,000) 0 (1,000,000) 0
Net cash used in investing activities (741,579) (1,998) (1,004,886) (9,298)
Cash flows from financing activities        
Proceeds from convertible note from Ampio converted to stock 0 3,700,000 7,400,000 4,600,000
Luoxis option payout pursuant to the merger     (27,476) 0
Liabilities paid out pursuant to the merger     (20,013) 0
Contribution from Ampio     0 637,210
Proceeds from convertible promissory notes, net (Note 8) 5,175,000 0    
Debt issuance costs (Note 8) (298,322) 0    
Ampio stock subscription payment 5,000,000 0 5,000,000 0
Sale of Stock subscription 200,000 0    
Costs related to the conversion of the convertible promissory notes to equity (29,754) 0    
Net cash provided by financing activities 10,046,924 3,700,000 12,352,511 5,237,210
Net change in cash and cash equivalents 1,312,774 (1,148,448) 4,713,411 (274,050)
Cash and cash equivalents at beginning of period 7,353,061 2,639,650 2,639,650 2,913,700
Cash and cash equivalents at end of period 8,665,835 1,491,202 7,353,061 2,639,650
Non-cash transactions:        
Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8) 102,931 0    
Primsol business purchase included in primsol payable, $1,250,000 less future accretion of $173,000 1,077,000 0    
Conversion of convertible promissory notes and interest of $143,000 to common stock 4,268,000 0    
Reclassification of liability based warrants to equity presentation related to the convertible promissory notes 87,000 0    
Beneficial conversion feature of $4,943,073 less $3,942,613 of accretion related to unconverted convertible promissory notes 1,001,000 0    
Debt issuance costs related to notes that converted to equity $ (183,000) $ 0    
Ampio stock subscription     5,000,000 0
Ampio unpaid debt converted to stock, received prior to 2015     4,600,000 0
Contingent consideration related to the ProstaScint purchase     664,000 0
Issuance of common stock in exchange for Vyrix acquired assets     0 6,803,356
Related party research and development liability included in prepaid research and development - related party     $ 0 $ 150,000